GILD

Gilead Sciences, Inc.NASDAQHealthcare

$139.71-0.42%OpenMarket Cap: $173.44B

As of 2026-04-06

Recent Analyst Ratings

Date	Firm	Action	Rating	Previous
2026-02-23	Needham	—	Buy	—
2026-02-11	RBC Capital	—	Sector Perform	—
2026-02-11	Wells Fargo	—	Overweight	—
2026-02-11	Truist Securities	—	Buy	—
2026-02-11	Scotiabank	—	Sector Outperform	—
2026-02-11	Cantor Fitzgerald	—	Overweight	—
2026-01-27	Citigroup	—	Buy	—
2026-01-26	UBS	—	Buy	—
2026-01-13	Morgan Stanley	—	Overweight	—
2025-12-12	Morgan Stanley	—	Overweight	—

Forward Estimates

Period	EPS Est.	Revenue Est.	# Analysts
Fri Dec 31	$9.66	$32.08B	18
Sun Dec 31	$10.50	$33.75B	9
Mon Dec 31	$11.68	$35.81B	3
Tue Dec 31	$12.67	$37.70B	3

GILD | Gilead Sciences, Inc. Analyst Ratings & Price Target - InvestLog